LTC1912640I2 - HDAC inhibitoriaus panobinostato panaudojimas mielomos gydymui - Google Patents

HDAC inhibitoriaus panobinostato panaudojimas mielomos gydymui

Info

Publication number
LTC1912640I2
LTC1912640I2 LTPA2016003C LTPA2016003C LTC1912640I2 LT C1912640 I2 LTC1912640 I2 LT C1912640I2 LT PA2016003 C LTPA2016003 C LT PA2016003C LT PA2016003 C LTPA2016003 C LT PA2016003C LT C1912640 I2 LTC1912640 I2 LT C1912640I2
Authority
LT
Lithuania
Prior art keywords
hdac inhibitor
myeloma treatment
inhibitor panobinostat
panobinostat
myeloma
Prior art date
Application number
LTPA2016003C
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37307336&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LTC1912640(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of LTC1912640I2 publication Critical patent/LTC1912640I2/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
LTPA2016003C 2005-08-03 2016-01-22 HDAC inhibitoriaus panobinostato panaudojimas mielomos gydymui LTC1912640I2 (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70522605P 2005-08-03 2005-08-03
PCT/US2006/029801 WO2007019116A1 (en) 2005-08-03 2006-08-01 Use of hdac inhibitors for the treatment of myeloma

Publications (1)

Publication Number Publication Date
LTC1912640I2 true LTC1912640I2 (lt) 2017-09-11

Family

ID=37307336

Family Applications (1)

Application Number Title Priority Date Filing Date
LTPA2016003C LTC1912640I2 (lt) 2005-08-03 2016-01-22 HDAC inhibitoriaus panobinostato panaudojimas mielomos gydymui

Country Status (18)

Country Link
US (2) US20080221126A1 (lt)
EP (1) EP1912640B1 (lt)
JP (2) JP5665271B2 (lt)
KR (1) KR101354237B1 (lt)
CN (2) CN104324025A (lt)
AU (1) AU2006278718B2 (lt)
BR (1) BRPI0614090A2 (lt)
CA (1) CA2617274C (lt)
DK (1) DK1912640T3 (lt)
ES (1) ES2545076T3 (lt)
HU (1) HUE028025T2 (lt)
LT (1) LTC1912640I2 (lt)
MX (1) MX2008001610A (lt)
PL (1) PL1912640T3 (lt)
PT (1) PT1912640E (lt)
RU (1) RU2420279C3 (lt)
SI (1) SI1912640T1 (lt)
WO (1) WO2007019116A1 (lt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5665271B2 (ja) * 2005-08-03 2015-02-04 ノバルティス アーゲー 骨髄腫の処置のためのｈｄａｃ阻害剤の使用
BRPI0807812A2 (pt) * 2007-02-15 2020-06-23 Novartis Ag Combinações de lbh589 com outros agentes terapêuticos para tratar câncer
KR101516446B1 (ko) * 2007-05-30 2015-04-30 노파르티스 아게 골 파괴의 치료를 위한 ｈｄａｃ 억제제의 용도
WO2010075286A1 (en) * 2008-12-24 2010-07-01 University Of Washington MOLECULAR ACTIVATORS OF THE Wnt/β-CATENIN PATHWAY
CN102762100B (zh) † 2009-11-13 2015-07-01 瑞塞普托斯公司 选择性的1-磷酸鞘氨醇受体调节剂及手性合成方法
KR20130101519A (ko) * 2010-09-01 2013-09-13 노파르티스 아게 Ｈｄａｃ 억제제와 혈소판감소증 약물의 조합물
MA41544A (fr) * 2015-02-19 2017-12-26 Novartis Ag Dosages de panobinostat pour le traitement du myélome multiple
US20180311257A1 (en) 2015-11-03 2018-11-01 Hochschule Darmstadt Selective hdac8 inhibitors and their uses
CN105348169B (zh) * 2015-11-16 2018-03-30 青岛大学 一种组蛋白去乙酰酶抑制剂(e)‑3‑(2‑(1‑(4‑氯苯甲酰基)‑5‑甲氧基‑2‑甲基‑1氢‑吲哚‑3‑基)乙酰氨基)‑n‑羟基丁‑2‑烯酰胺及其制备方法和应用
CN109705057B (zh) * 2017-10-25 2023-05-30 成都先导药物开发股份有限公司 组蛋白去乙酰化酶抑制剂及其制备方法与用途
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone
CN113164375A (zh) 2018-07-18 2021-07-23 希成生物医药 包含盐霉素的聚合物纳米颗粒
WO2022251844A1 (en) 2021-05-25 2022-12-01 Hillstream Biopharma, Inc. Polymeric nanoparticles comprising chemotherapeutic compounds and related methods

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020354A1 (es) * 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
PL392652A1 (pl) * 2001-05-16 2010-12-06 Novartis Ag Kombinacja zawierająca N-{5-[4-(4-metylo-piperazyno-metylo)-benzoiloamido]-2-metylofenylo}-4-(3-pirydylo)-2-pirymidyno-aminę oraz środek chemoterapeutyczny, jej zastosowanie, kompozycja farmaceutyczna ją zawierająca oraz zestaw zawierający taką kombinację
JP2005511062A (ja) * 2001-12-07 2005-04-28 ノバルティス アクチエンゲゼルシャフト タンパク質脱アセチル化酵素阻害剤についての生物マーカーとしてのアルファ−チューブリンアセチル化レベルの使用
US20040132825A1 (en) * 2002-03-04 2004-07-08 Bacopoulos Nicholas G. Methods of treating cancer with HDAC inhibitors
US20050043233A1 (en) * 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
JP2006528952A (ja) * 2003-05-21 2006-12-28 ノバルティス アクチエンゲゼルシャフト ヒストンデアセチラーゼ阻害剤と化学療法剤の組み合わせ
EP1667680A4 (en) * 2003-08-29 2008-10-08 Aton Pharma Inc COMBINED METHODS OF TREATING CANCER
WO2006102557A2 (en) 2005-03-22 2006-09-28 The President And Fellows Of Harvard College Treatment of protein degradation disorders
JP5665271B2 (ja) * 2005-08-03 2015-02-04 ノバルティス アーゲー 骨髄腫の処置のためのｈｄａｃ阻害剤の使用

Also Published As

Publication number Publication date
HUE028025T2 (en) 2016-11-28
ES2545076T3 (es) 2015-09-08
SI1912640T1 (sl) 2015-10-30
EP1912640B1 (en) 2015-06-17
KR20080031937A (ko) 2008-04-11
PT1912640E (pt) 2015-09-22
US8883842B2 (en) 2014-11-11
RU2420279C2 (ru) 2011-06-10
JP5876435B2 (ja) 2016-03-02
JP2013173757A (ja) 2013-09-05
CA2617274C (en) 2017-10-10
RU2420279C3 (ru) 2017-03-14
AU2006278718B2 (en) 2010-10-07
BRPI0614090A2 (pt) 2011-03-09
JP2009503087A (ja) 2009-01-29
KR101354237B1 (ko) 2014-01-22
MX2008001610A (es) 2008-02-19
AU2006278718A1 (en) 2007-02-15
CA2617274A1 (en) 2007-02-15
EP1912640A1 (en) 2008-04-23
RU2008107871A (ru) 2009-09-10
DK1912640T3 (en) 2015-09-14
WO2007019116A1 (en) 2007-02-15
PL1912640T3 (pl) 2015-11-30
US20080221126A1 (en) 2008-09-11
CN101232880A (zh) 2008-07-30
CN104324025A (zh) 2015-02-04
JP5665271B2 (ja) 2015-02-04
US20100160257A1 (en) 2010-06-24

Similar Documents

Publication Publication Date Title
LTC1912640I2 (lt) HDAC inhibitoriaus panobinostato panaudojimas mielomos gydymui
DK1940839T3 (da) Pyridopyrimidione Inhibitors of P13Ka
BRPI0719204A2 (pt) Inibidores de hdac
SI1928872T1 (sl) Novi sulfonilpiroli kot inhibitorji HDAC
CY2016017I2 (el) Συνθεση για θεραπεια πνευμονικης υπερτασης
CY2014011I2 (el) Χορηγηση αναστολεων διπεπτιδυλοπεπτιδασης
SMAP200900058A (it) Composti e composizioni come inibitori di proteinachinasi
SM201000108B (it) Composti e composizioni come inibitori di proteinachinasi
SMAP200900020A (it) Composti e composizioni come inibitori di proteinachinasi
SMAP200900031A (it) Composti e composizioni come inibitori di proteinachinasi
ATE434620T1 (de) Dihydrothienopyrimidine zur behandlung von entzündlichen erkrankungen
ATE521238T1 (de) Kristalline modifikationen des pyraclostrobins
CR10831A (es) INHIBIDORES ESPIRO CETONA DE ACETIL-CoA CARBOXILASA
DK2041138T3 (da) Pyrroltriazinkinase-inhibitorer
DK2024375T3 (da) Cyclopropyl-kondenserede indolobenzazepin-HCV-NS5B-hæmmere
SMAP200900085A (it) 3-imidazolil-indoli per il trattamento di malattieproliferative
DK1685834T3 (da) Anvendelse af pinolensyre til behandling af obesitet
BRPI0717460A2 (pt) Composições de inibidores de chk1
DK2099796T3 (da) Aza-indolyl-forbindelser og fremgangsmåder for anvendelse
DK2034830T3 (da) Anti-vla-1-antistof til behandling af slagtilfælde
DK2066662T3 (da) Serinhydrolaseinhibitorer
ATE418545T1 (de) Nnrt-inhibitoren
FI20055133A0 (fi) Iskulaite
IL201466A0 (en) Use of hdac inhibitors for the treatment of bone destruction
DE602007003350D1 (de) Behandlung von polysilazan-abfall